The Medical Opportunity Flying Under Wall Street’s Radar

FN Media Group Presents Market Commentary


London – December 4, 2020 –  Depression is now the number one disability in the world. And it’s costing the economy $1 trillion in lost production every single year. Yet, a classical compound that even the FDA has twice recently called a “breakthrough therapy” is shaping up to be the revolutionary treatment that big pharma has been waiting for. And it’s being backed by what Forbes describes as Silicon Valley legends, billionaire financiers and patent attorneys.   Mentioned in today’s commentary includes:  Aurora Cannabis Inc. (NYSE: ACB), Canopy Growth Corporation (NASDAQ: CGC), Tilray, Inc. (NASDAQ: TLRY), Cronos Group Inc. (NASDAQ: CRON), Aphria Inc. (NASDAQ: APHA).


Right on the leading edge of this trillion-dollar biotech transformation is Lobe Sciences (LOBE; GTSIF). The company is working in partnership with the University of Miami towards a revolutionary treatment for globally crippling depression. But this is a game of patents, with multi-billion-dollar IP at stake, and Lobe already has 5 provisional patent applications on their technology already.


$16 Trillion in Mental Health Spending Is Demanding Better Treatments


Four classic compounds will “revolutionize the treatment of mental health diseases”, says Lobe’s chief scientist, Maghsoud Dariani. “With just one of these compounds we’re already seeing significant decreases in symptoms and successful outcomes.”


The four compounds are CBD, THC, MDMA and psilocybin. And they’re all being fast-tracked for medical use right now. The first two compounds, CBD and THC already made tons of money for investors in the initial cannabis boom:


  • 9,000% gains on Cronos Group
  • Over 2,300% gains on Aphria
  • Over 1,500% gains on Canopy Growth


But the fourth compound–psilocybin–is the next big push we’re looking at. This is the potential treatment for a litany of global mental health issues that the world will spend $16 trillion on.


  • More than 264 million people are suffering from depression at this very moment, according to the World Health Organization.
  • 1 in 13 people will develop PTSD at some point in their life.
  • During the global pandemic… 1 in 20 women… and 1 in 50 men were newly diagnosed.
  • Depression is now the No. 1 cause of disability in the world.


The ‘Miracle Compound’ Now Has Science Behind It


The science is there. A ground-breaking Johns Hopkins study started it all off. The 2016 study concluded that psilocybin eased depression and anxiety in patients with life-threatening cancer.


That opened the scientific research floodgates:


  • A study in the Journal of Psychopharmacology demonstrated a single psilocybin dose that produced an antidepressant and anxiolytic response in cancer patients.
  • The University of South Florida found this compound to be highly effective because it binds to certain brain receptors and stimulates healing and growth.
  • According to Alan Davis, the author of the study and a faculty member at Johns Hopkins University and Ohio State University, psilocybin’s effect was “more than four times greater”.


Lobe Sciences is focusing on the multi-billion-dollar PTSD, depression and anti-anxiety market, and it’s working with pioneering scientists to create the first treatment that truly resets the brain for PTSD sufferers, before they show symptoms.


Lobe Sciences is hoping its psilocybin studies will achieve the 80% (or higher) success rate that we’re now seeing published in medical journals. That’s the same rate Johns Hopkins achieved with its cancer patients.


The Golden Era of Brain Science


High-profile angel investor Tim Ferriss has so far given $2 million to Johns Hopkins’ psychedelic research center, which he refers to as the “Silicon Valley of psychedelics” where they are rigorously studying psilocybin for a wide range of applications:


Brad Loncar, a massively influential biotech investor, called this Big Pharma win the “ultimate sign for investors” to jump in on psilocybin. Loncar is not alone, either. Among a lengthening lineup we’ve already seen multi-billionaire and PayPal co-founder Peter Thiel and billionaire investor Mike Novogratz pile in.


The industry has already been validated, and this space is heating up fast. And Lobe Sciences (LOBE; GTSIF) is extremely well-positioned. In addition to coming up with a concept for a transformational approach to PTSD treatment, it has a provisional patent application for a nasal mist transducer device that allows for specific doses of medicines to be sprayed into the nasal cavity and rapidly enter the bloodstream.


Massive ‘Miracle Compound’ Momentum


Smart money is definitely watching closely for new entrants.  They’re eyeing it as one of the biggest opportunities of 2021. They like the science that’s finally been let loose. They recognize the massive mental health problem. And they’ll be looking for patents and targets for Big Pharma acquisitions.


It’s got the backing of Big Science, with Johns Hopkins pouring a massive amount of effort and money into R&D. It’s already got Big Pharma. It’s even got the FDA on its side. All of these catalysts put Lobe Sciences (LOBE; GTSIF) in the position to potentially be one of the first stocks to benefit from the massive news flow coming out of the sector.


Cannabis Companies Have Experienced The Legalization Magic First Hand


Aurora Cannabis (ACB) is one of the biggest names in the burgeoning marijuana sector. With a market cap over $1.29 billion, Aurora has carved out its position as a leader in the industry. Over the past couple of years, Aurora has completed a number of high-profile takeovers, including the buyout of CanniMed and MedReleaf. And the company is still making moves.


Recently, Aurora closed a $173 million public offering to fund new growth opportunities in the sector, selling 23 million shares at $7.50 per unit. And the timing is perfect as a number of U.S. states have just approved new regulations surrounding medical and recreational cannabis use.


Contrary to Aurora, Canopy Growth Corporation (CGC) has had a pretty stellar year. Though the company posted a lost in year-over-year revenue, its stock price has remained resilient thanks to its big-name partnerships. In fact, just this year, beverage giant Constellation Brands, increased its stake in the cannabis producer to 38.6%


Bill Newlands, president and CEO of Constellation Brands explained, “While global legalization of cannabis is still in its infancy, we continue to believe the long-term opportunity in this evolving market is substantial.”


Thanks to these strategic moves, Canopy has seen its share price jump from its March low of $10.37 to today’s near-yearly high of $24.04, representing a 131% increase for investors who jumped in at the right time.


Tilray Inc. (TLRY) is another leader in Canada’s cannabis industry. With a near-billion-dollar market cap, Tilray is well-positioned to benefit from the ongoing wave of legalization – both medicinal and recreational – in the United States. Following the recent elections, five more states voted to legalize medical or recreational cannabis, and Tilray is optimistic that other states will follow.


CEO Brendan Kennedy noted, “Adult-use legalization in New Jersey is likely to have a domino effect on the states of New York, Pennsylvania, and Connecticut, as elected officials are worried that their residents will go to New Jersey to purchase product and thereby not generate tax dollars in their home state.”


Following its July slump, Cronos Group (CRON) has seen a surge in trading volume, with a renewed investor interest which has also been reflected in its share price. Since September, the company has seen its share price jump from $5.04 to a price of $7.23 today.


The Canadian firm, though primarily an equity investor, has made some major moves in recent years, wheeling and dealing with some of the hottest names in the sector. Because of its forward-thinking attitude, it has drawn the attention of many major mainstream players, including the company behind Marlboro, Altria Group, which purchased a 45% stake in the company in 2018 for a total of $2.4 billion.


Aphria Inc (APHA), currently valued at just over $1.9 billion, is a giant in the industry. Thanks to its big-picture approach to the industry, Aphria has been able to thrive while many of its peers have stumbled.


Recently, in anticipation of wider U.S. legalization, Aphria entered into a $300 million deal to aquire SweetWater Brewing, one of the biggest craft beer brewers in the United States. The purchase aims to help Aphria capitalize on the growing “lifestyle” market associated with both craft beer and high-end cannabis.




PAID ADVERTISEMENT. This article is a paid advertisement. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Lobe Sciences to conduct investor awareness advertising and marketing. Lobe paid the Publisher to produce and disseminate five similar articles and additional banner ads at a rate of sixty thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Lobe) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.


SHARE OWNERSHIP. The Publisher owns shares and/or stock options of the featured companies and therefore has an additional incentive to see the featured companies’ stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.


FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to differ include, but are not limited to, changing governmental laws and policies impacting the company’s business including the legality of Psilocybin and other psychedelics, the ability of the company to exercise or sell its option to acquire shares of Cowlitz County Cannabis Cultivation or otherwise monetize its interest in Cowlitz, the degree of success with research and development of the company’s medicines and devices, the success of clinical trials, governmental approval or clearance of the company’s medicines and devices, the size and growth of the market for the companies’ products and services, the ability of management to execute its business plan, the continuity of management, the companies’ ability to fund its capital requirements in the near term and long term, pricing pressures, etc.


INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.


TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


INTELLECTUAL PROPERTY. is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.


DISCLAIMER: is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein.  The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.


Contact Information:

Media Contact e-mail:  U.S. Phone: +1(954)345-0611